SUBMITTED TO: MRS.

NEHA SHAW

SUBITTED BY: GROUP 1 M(12) RITIKA VIKRAM SINGH SEEMA RAVI SHAEKAR SRIVASTVA VANDANA AZAD

ABOUT PFIZER
Pfizer, Inc. is an American multinational pharmaceutical corporation. Its HEADQUARTERS are in MIDTOWN MANHATTAN in New York City, New York with its research headquarters in Groton, Connecticut, United States. y It was been founded in1849. y Its PRESIDENT & CEO is Ian Read. y In India :Headquartered in Mumbai
y

ITS CONTRIBUTION
y Societal Contribution:-It helps society by facilitating

availability of the required drug by the people. y Academic Contribution:Academy of Clinical Excellence (ACE) 2. Indian Society for Clinical Research (ISCR)
1.

ITS DISGRACEFUL EVENTS

y Pfizer pleaded guilty in 2009 to the largest health

care fraud in U.S. history and received the largest criminal penalty ever levied for illegal marketing of four of its drugs. Called a repeat offender, this was Pfizer's fourth such settlement with the U.S. Department of Justice in the previous ten years. On January 26, 2009, Pfizer agreed to buy pharmaceutical giant Wyeth for US$68 billion, a deal financed with cash, shares and loans. The deal was completed on October 15, 2009.

STRENGTH
number one pharmaceutical from sales point of view. its marketing infrastructure is well established throughout the world. Pfizer has 7.5% of ranking corporation market share. global working network with 95,000 workers around the globe, in all the continents. Their research and development sector is highly established and in good strength, wide range of area being worked, that includes Human health, animal health, customer health and corporate groups.

WEAKNESSES
In latter stages of production they often discontinue the activity, increasing its demand. Not specifically working in the area of primary concern in the drug markets including CV and CNS. Its co marketing with other companies and merging with other pharmaceuticals can halter its global popularity.

OPPORTUNITIES
Pfizer is reconstructing its strategically approach by cutting the manufacture cost. High profits, revenues and funds are available to uplift the companys progress. Expansion of the biologic pharmacy market. Marketing agreements with the leading companies.

THREATS
Illegal marketing of Pfizers drugs makes it potent not to be reliable, & for that they had to pay the biggest ever penalty in the history of U.S. Pfizer is losing its patent individuality by focusing on one product. Same products are available at cheaper rates by other brands. Outstanding competition of regional markets along with emerging markets of India and China.

y In 2000 Pfizer took over WarnerLambert, a drug

store. y In 2002, Pfizer merged with Pharmacia. y On January 26, 2009, Pfizer agreed to buy pharmaceuticals rival Wyeth. The acquisition was completed on October 15, 2009 making Wyeth a wholly owned subsidiary of Pfizer. y In October 2010, Pfizer agreed to buy King Pharmaceuticals.

ITS SUBSIDIARIES
y Its subsidiaries are:

Agouron Pharmaceuticals, G. D. Searle & Company, Greenstone, Parke-Davis, Pharmacia, Upjohn, Warner Lambert, Wyeth.

y The company has three business segments : health care, y y

animal health and consumer health care. In 2001, Pfizer increased its market share and became the sales leader. The main reason for their tremendous growth is that their pharmaceutical products are able to improve the quality of life of their customers. Pfizer spent 7.1 billion on Research & Development in 2003 - this is the only pharmaceutical company that is capable of investing this much. They are deeply committed to meeting the needs of their customers and constantly focus on customer satisfaction.

y Fortune named Pfizer as the fifth-best wealth-creator in y y

America. Pfizers foreign market expanded into 100 countries and accounted for $175 million (199 million) in sales by 1965. In 2000, its revenues equaled $29,6 billion (20,14bn), eight of Pfizers pharmaceutical products attained sales of at least $1 billion (680,4 million) each. In 2001, Pfizer has budgeted approximately $5 billion (3,402bn) for research and development - more than any other drug company in the world. According to the Financial Times (26 April 2001), Pfizer has powered its way up the global ranking list to its unassailable position thanks mainly to its marketing skill. The company profits has gradually been improved from $48.2 billion in 2008 to $50 billion in 2009 and then jumping directly to 67.8 billion, which means that its sale has increased from 16.02 to 22.89 %, which is the big achievement in rising revenues.

Product Name
    

Use
for hypertension treatment for Alzheimers disease for arthritis for cholesterol & hypertension for cancer & Chemotherapeutic agents For HIV for asthma for diabetes & insulin therapies for birth control

(i) Accupril , (ii) Norvasc Aricept (i) Bextra , (ii) Celebrex Caduet Camptosar (i) Rescriptor , (ii) Selzentry (i) Depo-Medrol , (ii) Solu-Medrol DepoSoluExubera

 

Depo Provera

List of Animal Health Brands manufactured by Pfizer :

y Bovi-Shield Gold y Cerenia y Convenia y Dectomax y Draxxin y Excede y Excenel y Inovocox y Mycitracin y Palladia y Pirsue y A180 y Revolution Pet Medicine y Rimadyl y Simplicef y Slentrol y Solitude IGR y Spectramast y Stellamune y Stronghold

2002 : y Pfizer Inc Named One of the "100 Best Companies to Work for in America" Fortune y Fortune magazine ranks Pfizer 12 on list of Global Most Admired Companies. 2002 : y Pfizer Most Admired Pharmaceutical Company MedAdNews 2005 : y Fortune magazine ranks Pfizer 24 on the list of top revenue-earning companies in the U.S. and at the top of the pharmaceutical industry. y The Scientist news journal ranks Pfizer 5 on the list of top ten large companies in the Best Places to Work in Industry survey. 2011 : y Pfizer ranked first in the medicine and health care industry in an annual ranking conducted by Antal International, a global executive search firm.

ITS VISION
Its vision is to be recognized for meeting the diverse medical needs of patients in Emerging Markets around the world in an innovative, socially responsible and commercially viable manner.

CONSUMER SOCIAL RESPONSIBILTY

Pfizer India actively supports a variety of programmes and initiatives that make a difference to communities in need. Pfizer Indias community development initiatives include: y Providing access to medicines y Support to cancer patient groups y Providing health literacy and spreading disease awareness y Education, training and capacity-building

MARKET SEGMENTATION
Human Health, 2. Animal Health, 3. Consumer Healthcare:On June 26, 2006, Pfizer announced that it would sell its Consumer Healthcare unit (manufacturer of Listerine, Nicorette, Visine, Sudafed and Neosporin) to Johnson & Johnson for $16.6 billion.
1.

MARKET TARGET
TARGET MARKETS:1. Potential Breakthrough in Big Markets including:Atherosclerosis,Oncology,Diabetes,Obestiy ,Rheumatoid Arthritis,HIV,Schizophrenia,Liver Disease,Alzheimers Diesease. 2. Targeting Four New Products Annually.

MARKET POSITIONING
y PFIZER POSITIONING:- The acquisition of Pfizer's

consumer Health business by J&J can be explained by the differing strategy of the two companies. While the two companies directly compete with each other they envision dramatically different ways in which to maximize shareholder value over the long-term.

PFIZER MISSION
PFIZER MISSION STATEMENT: "We will become the world's most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live."